Thalidomide News and Research

RSS

Thalidomide is a drug that is used to treat multiple myeloma in patients who have just been diagnosed, and a painful skin disease related to leprosy. It is also being studied in the treatment of other types of cancer. Thalidomide belongs to the family of drugs called angiogenesis inhibitors. Also called Thalomid.

Molecules wrestle for supremacy to dictate the physical state of superstructures

Research at the University of Liverpool has found how mirror-image molecules gain control over each other and dictate the physical state of superstructures.

13 Aug 2009

Thalidomide does not improve survival in small cell lung cancer

Treating patients with thalidomide in combination with chemotherapy for small cell lung cancer (SCLC) did not improve their survival but did increase their risk of blood clots, according to a new study published online July 16 in the Journal of the National Cancer Institute.

17 Jul 2009

Separating the good from the bad

Scientists at MIT and Brown University studying how marine bacteria move recently discovered that a sharp variation in water current segregates right-handed bacteria from their left-handed brethren, impelling the microbes in opposite directions.

15 Apr 2009

Is human ‘imperfection’ such a bad thing?

Imagine a world of 'human perfection' where disabled people are a distant memory, edited out by medical enhancement and economic cost-benefit analysis: a world where thanks to generic selection and economic crises disabled people find themselves expendable.

19 Jan 2009

Lessons from Northwick Park drug-trial disaster

Scientists investigating the 2006 Northwick Park drug-trial disaster that left six healthy volunteers hospitalised say they have developed new pre-clinical tests that could have stopped the trial from ever going ahead.

From The University of Manchester 15 Dec 2008

$Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma$

Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma

Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma.

10 Dec 2008

Controlling the building blocks of life

A simple and reliable method for converting one of the simplest chemical entities into one of the most difficult-to-make molecular building blocks of life, with complete control over its shape, is reported by scientists at the University of Bristol in this week's Nature.

10 Dec 2008

New data on ZOLINZA (vorinostat) in combination with Bortezomib

Results from two Phase 1 studies of ZOLINZA (vorinostat), Merck's oral histone deacetylase (HDAC) inhibitor, administered in combination with bortezomib, showed early anti-tumor activity in patients with relapsed and/or refractory multiple myeloma, including those previously treated with and no longer responding to bortezomib.

10 Dec 2008

Drug combo improves or stabilizes disease for relapsed multiple myeloma patients

Mayo Clinic researchers have found that a new combination of medications designed to maximize immune functions improved or stabilized multiple myeloma for 76 percent of patients who had relapsed after previous treatment.

10 Dec 2008

FDA deadlines may compromise drug safety by rushing approval

Many medications are approved by the U.S. Food and Drug Administration on the brink of congressionally mandated deadlines, and those drugs are more likely to face later regulatory intervention than those approved with greater deliberation, researchers at Harvard University have found.

28 Mar 2008

Thalidomide shows promise for treatment of recurrent ovarian cancer

Thalidomide, a drug blamed in the 1950s for causing birth defects, is now showing promise as a safe and effective treatment for women with recurrent ovarian cancer, according to a study led by a University of Minnesota Cancer Center researcher.

28 Feb 2008

New way to grow blood vessels

Researchers at Dana-Farber Cancer Institute have found a previously unknown molecular pathway in mice that spurs the growth of new blood vessels when body parts are jeopardized by poor circulation.

21 Feb 2008

Velcade, lenalidomide and dexamethasone combo show promise for multiple myeloma

A new combination of bortezomib (Velcade) and two other drugs is showing a very high response rate in patients newly diagnosed with multiple myeloma, a team headed by Dana-Farber Cancer Institute investigators reported at the annual meeting of the American Society of Hematology.

13 Dec 2007

Lenalidomide - dexamethasone combination effective against multiple myeloma

Pairing a new thalidomide derivative with a steroid slows progress of multiple myeloma, an incurable bone marrow cancer, and prolongs the lives of patients who have relapsed from previous treatment, researchers report in the Nov. 22 New England Journal of Medicine.

21 Nov 2007

Studies attribute recent increase in multiple myeloma survival to novel therapies

Multiple myeloma is one of the most common and devastating bone marrow cancers in the U.S., but survival rates have risen dramatically over the past decade.

2 Nov 2007

Thalidomide therapy helps elderly myeloma patients live longer

The drug thalidomide is making a comeback as a cancer fighting therapy and has been successfully used along with standard therapy to treat the blood cancer myeloma.

7 Oct 2007

New pregnancy labeling rules should be approved without delay

Marks the tenth anniversary of a public hearing that was hoped to spark substantial changes in the way drugs are labeled for use during pregnancy.

2 Aug 2007

50 million Europeans suffer from neurological diseases

About 50 million people in the EU suffer from neurological diseases such as epilepsy, migraines, multiple sclerosis, Parkinson's disease, strokes and dementia.

18 Jun 2007

Multiple myeloma dexamethasone / lenalidomide trial closes

The Southwest Oncology Group, the largest of several National Cancer Institute-sponsored clinical trials networks, has permanently closed enrollment in a trial comparing a standard drug therapy, dexamethasone, with a combined therapy of the same drug plus the drug lenalidomide (Revlimid) for people newly diagnosed with multiple myeloma.

16 May 2007